Changming An
YOU?
Author Swipe
View article: cGAS-STING pathway reprograms macrophage polarization and is highly expressed in responding tumors after neoadjuvant immunotherapy in head and neck carcinoma
cGAS-STING pathway reprograms macrophage polarization and is highly expressed in responding tumors after neoadjuvant immunotherapy in head and neck carcinoma Open
Given the critical role of the cGAS-STING pathway in antitumor immunity, this study investigates the functional role of STING in head and neck squamous cell carcinoma (HNSCC) to evaluate the therapeutic potential of STING agonists. Analysi…
View article: Application of optimized postoperative drainage pressure combined with parathyroid function monitoring in enhanced recovery after surgery for thyroid cancer: A prospective randomized controlled study
Application of optimized postoperative drainage pressure combined with parathyroid function monitoring in enhanced recovery after surgery for thyroid cancer: A prospective randomized controlled study Open
Background Postoperative drainage management and hypocalcemia monitoring are critical factors influencing enhanced recovery after surgery (ERAS) following thyroidectomy. This study aimed to evaluate the effects of different drainage pressu…
View article: Neoadjuvant toripalimab combined with chemotherapy in locally advanced HNSCC
Neoadjuvant toripalimab combined with chemotherapy in locally advanced HNSCC Open
Introduction To determine the safety and efficacy of neoadjuvant toripalimab combined with chemotherapy in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Patients and methods This single-arm investigator-initiated trial…
View article: Supplementary Table S2 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Supplementary Table S2 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study Open
Confirmed best overall response per RECIST v1.1
View article: Supplementary Figure S4 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Supplementary Figure S4 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study Open
Univariate association analysis for progression-free survival
View article: Supplementary Figure S1 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Supplementary Figure S1 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study Open
Flow diagram of patient disposition
View article: Supplementary Figure S2 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Supplementary Figure S2 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study Open
Next-Generation Sequencing results
View article: Data from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Data from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study Open
Purpose:Patients with recurrent or metastatic sinonasal squamous cell carcinoma (R/M SNSCC) lack standardized systemic treatment and prospective studies. We evaluated the antitumor response and safety of pembrolizumab with nab-paclitaxel a…
View article: Supplementary Figure S3 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Supplementary Figure S3 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study Open
Univariate association analysis for overall survival
View article: Supplementary Table S1 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Supplementary Table S1 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study Open
Representativeness of Study Participants
View article: Supplementary Figure S5 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Supplementary Figure S5 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study Open
Treatment in representative patient
View article: Supplementary Table 11 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Table 11 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Accuracy of [68Ga]Ga-CTR-FAPI PET-CT and traditional imaging in identifying MTC or non-MTC lesions
View article: Supplementary Table 2 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Table 2 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Detection rate of patients with calcitonin
View article: Supplementary Table 13 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Table 13 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Safety of the PET-CT regimens
View article: Supplementary Figure 3 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Figure 3 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Correlation between [68Ga]Ga-CTR-FAPI uptake and FAP expression
View article: Supplementary Table 12 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Table 12 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Pre- and post-surgical calcitonin level of surgical patients
View article: Supplementary Table 5 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Table 5 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Inter-reader agreement
View article: Supplementary Table 7 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Table 7 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Tumor uptake stratified by calcitonin levels
View article: Supplementary Figure 1 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Figure 1 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Patient-based and region-based detection rates
View article: Supplementary Table 8 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Table 8 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Tumor uptake stratified by CEA levels
View article: Notification to AttendingPhysician from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Notification to AttendingPhysician from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Notification to Attending Physician
View article: Data from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Data from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Medullary thyroid carcinoma (MTC) can only be cured through the excision of all metastatic lesions, but current clinical practice fails to localize the disease in 29% to 60% of patients. Previously, we developed a fibroblast activation pro…
View article: Supplementary Table 9 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Table 9 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Tumor uptake stratified by newly diagnosed or persistent MTC
View article: Supplementary Table 4 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Table 4 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Detection rate of patients with calcitonin >2000 pg/ml
View article: Supplementary Figure 2 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Figure 2 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Lesion uptake of [18F]FDG and [68Ga]Ga-CTR-FAPI
View article: Supplementary Table 10 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Table 10 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Presurgical imaging identification of the 60 lesions
View article: Supplementary Table 14 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Table 14 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Representativeness of study participants
View article: Supplementary Table 1 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Table 1 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Baseline characteristics of the enrolled patients
View article: Clinical Protocol from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Clinical Protocol from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Clinical Protocol
View article: Supplementary Table 3 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
Supplementary Table 3 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma Open
Detection rate of patients with calcitonin 500 to 2000 pg/ml